MarketInOut Stock Screener Log In | Sign Up

Pelthos Therapeutics Inc

NYSE • Healthcare • Biotechnology • Quote as of 10/30/2026
Pelthos Therapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNYSE
Market Capitalization37.12 mln
Float1.69 mln
Earnings Date11/12/2026

Piotroski F-Score

4 / 9
Borderline

1-Year Forecast

49.57
Transformational upside

Relative Strength

1 / 100
Severely lagging

Pre-Tax Margin

-217%
Severely loss-making

ROE

-390
Deeply negative

Altman Z-Score

-2.39
Deeply distressed

Business Description

Pelthos Therapeutics Inc. is a Durham, North Carolina-based pharmaceutical company founded in 2002 that focuses on developing and selling treatments for skin conditions in both adults and children. Its approved products include therapies for molluscum contagiosum, impetigo, and head lice, covering patients from infancy onward. The company also owns a proprietary nitric oxide technology platform that supports its ongoing research efforts.

Key Fundamentals

EPS-27.53
ROE-390
RPS13.21
ROIC-69.85
ROA-79.92
Interest Cover-7.81
EBITDA, mln-81.06
EV / EBITDA-1.22
EV / EBIT-1.15
Revenue, mln43.30
EV / Revenue2.29

Quote Details

Last 9.40
Change -7.14 (-43.17%)
Open 18.72
Volume 241,199
Turnover 2,267,270
Average Volume 64,258

Financial Ratios

Pre-Tax Profit Margin-217
Current Ratio1.98
Price / Sales1.10

Financial Strength

Altman Z-Score-2.39
Piotroski F-Score 4 / 9
1-Year Target Price49.57
Short Ratio3.73
Short % of Float6.88

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -44.71% 1 / 100   
1 Month -53.81% 3 / 100   
2 Months -65.93% 4 / 100   
6 Months -62.4% 9 / 100   
1 Year -70.62% 12 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog